CD79B

Across TCGA pan-cancer cohorts, CD79B Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CD79B data layer compared with 25 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CD79B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD79B expression acts as an unfavorable survival marker.

DLBC, SCLC, and LIHC are the cancer types where CD79B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.070	0.887	<.001	45	view →
SCLC	DFS	Median	All	0.164	0.631	.002	33	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
SKCM	OS	Median	II,III,IV	0.444	0.742	.021	7	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
THCA	DFS	Median	All	0.196	0.830	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CD79B–DLBC (DFS)

Open the DLBC breakdown →